Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ottawa Heart Institute Research Corporation
Treatment group: Prior to the initiation of AST, subjects will have a baseline N-13-ammonia PET scan and a brachial artery ultrasound at the University of Ottawa Heart Institute. Blood glucose and a lipid profile will be obtained. These tests will be repeated 6 - 9 months after starting AST.
Cancer control group: The same testing and intervals will be performed. Normals control group: Baseline testing will be done to establish a normal.
Age
40–80
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Cancer Population:
1. Diagnosis of prostate cancer
2. Treatment group: Scheduled to start AST, at Ottawa Hospital under the care of Radiation Oncology, Urology or Medical Oncology.
Control group: no AST scheduled as a treatment option for prostate cancer.
Non-Cancer Control Group
1. Male with low pre-test likelihood of coronary artery disease
2. No previous history of cancer.
You may not be if
1. Known coronary disease including any of previous revascularization, history of myocardial infarction, coronary disease with \>= 50% stenosis in a major coronary vessel on previous angiography, evidence of previous myocardial infarction on 12-lead electrocardiogram, positive myocardial perfusion scan, previous cardiac PET scan, stress echocardiogram or exercise stress test.
2. Subjects with a Summed Stress Score of \>4 attributed to coronary disease on baseline PET images
3. Patients previously treated with AST
4. Patients with a life expectancy of less than 1 year.
Clareo Health | Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
